
In a recent study, researchers suggest that weekly paclitaxel can be a safe and effective treatment for pregnancy-associated breast cancer (PrBC), providing an alternative to anthracycline-based chemotherapy. Out of eighteen patients treated with weekly paclitaxel, none experienced severe adverse reactions. However, two cases of preterm prelabour rupture of membranes were reported, and in one case, treatment was stopped due to threatened preterm birth. Despite these complications, the majority of babies had normal birth weights. The study concludes that weekly paclitaxel should be considered as a viable treatment option for PrBC, offering benefits for both maternal and fetal well-being.
Like
Save
Share